(Q42064952)

15 October 2017

0 references

Value of drug level testing and antibody assays in optimising biological therapy (English)

1 reference

15 October 2017

1 reference

Séverine Vermeire

1

1 reference

PMC publication ID

3533399

15 October 2017

Ann Gils

series ordinal

2

1 reference

15 October 2017

5 September 2012

1 reference

Frontline gastroenterology

15 October 2017

1 reference

15 October 2017

4

1 reference

15 October 2017

1

1 reference

15 October 2017

41-43

1 reference

Immunogenicity of biological therapeutics: from assay to patient

15 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3533399

Doubling the infliximab dose versus halving the infusion intervals in Crohn's disease patients with loss of response.

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3533399

Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort.

17 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3533399

Early serial trough and antidrug antibody level measurements predict clinical outcome of infliximab and adalimumab treatment: Table 1

17 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3533399

Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: Definitions, frequency and pharmacological aspects

1 December 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3533399

Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease

1 December 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3533399

Therapeutic drug monitoring of infliximab in spondyloarthritis: an observational open-label study

1 December 2018

1 reference

12 December 2020

Clinical implications of variations in anti-infliximab antibody levels in patients with inflammatory bowel disease

1 reference

12 December 2020

Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease

1 reference

12 December 2020

Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis

1 reference

12 December 2020

Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease

1 reference

12 December 2020

10.1136/FLGASTRO-2012-100241

Identifiers

DOI

1 reference

15 October 2017

1 reference

PMC publication ID

3533399

15 October 2017

PubMed publication ID

23293739

1 reference

PMC publication ID

3533399